Evidence map›Paper›PMID 39567530›Full record

ArticleNPJ vaccines2024

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates.

Marco Polo Peralta-Álvarez, Keya Downward, Andrew White, Hugo Redondo Azema, Laura Sibley, Charlotte Sarfas, Alexandra Morrison, Mike Dennis, Delia Diaz-Santana, Stephanie A Harris and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marco Polo Peralta-ÁlvarezJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-2777-9272
Keya DownwardJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0009-8818-7853
Andrew WhiteUK Health Security Agency, Porton Down, Salisbury, UK.ORCID http://orcid.org/0000-0001-9481-0079
Hugo Redondo AzemaJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0004-5361-0360
Laura SibleyUK Health Security Agency, Porton Down, Salisbury, UK.
Charlotte SarfasUK Health Security Agency, Porton Down, Salisbury, UK.
Alexandra MorrisonUK Health Security Agency, Porton Down, Salisbury, UK.
Mike DennisUK Health Security Agency, Porton Down, Salisbury, UK.
Delia Diaz-SantanaDepartment of Biology, University of Oxford, Oxford, UK.
Stephanie A HarrisJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Shuailin LiJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-7430-1717
Eugenia PuentesClinical Research Department y Research and Development Department, Biofabri, Grupo Zendal, O'Porriño, Pontevedra, Spain.
Nacho AguiloFaculty of Medicine, University of Zaragoza, Zaragoza, CIBERES, Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0001-7897-9173
Carlos MartinFaculty of Medicine, University of Zaragoza, Zaragoza, CIBERES, Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0003-2993-5478
Sally SharpeUK Health Security Agency, Porton Down, Salisbury, UK.
Helen McShaneJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2126-5142
Rachel TannerJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. rachel.tanner@biology.ox.ac.uk.ORCID http://orcid.org/0000-0003-3622-5984

Funding

Wellcome TrustWellcome Trust (Wellcome) WT 206331/Z/17/Z
6 · The paper itself

Abstract

The only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline. It is more efficacious than BCG in preclinical models including non-human primates (NHPs), and has demonstrated safety and immunogenicity in human populations. To better understand the immune mechanisms underlying the superior efficacy conferred by MTBVAC, we characterized M.tb-specific antibody responses in NHPs vaccinated with either BCG or MTBVAC. MTBVAC vaccination induced higher titers of IgG, IgM and IgA, and higher avidity IgG compared with BCG vaccination. IgG avidity correlated with protection following M.tb challenge in the same animals, validating the association previously reported between this measure and protection in the context of intravenous BCG vaccination, suggesting that IgG avidity may represent a relevant marker or correlate of protection from TB.

Identifiers

PMID39567530
PMCPMC11579480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.